Unmasking latent extrapulmonary tuberculosis with newly diagnosed HIV-1 infection in a COVID-19 patient with prolonged fever

Kaiho Hirata1, Koji Watanabe2, Takeshi Sasaki1, Takashi Yoshimasu3, Akihiko Shimomura4, Naokatsu Ando5, Yasuaki Yanagawa1, Daisuke Mizushima1, Katsuj Teruya1, Yoshimi Kikuchi1, Shinichi Oka1 and Kunihisa Tsukada1

1AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
2374th Medical Group, Yokota Air Force Base, Tokyo, Japan
3Department of Obstetrics and Gynecology, Teine Keijinkai Hospital, Hokkaido, Japan
4Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan
5Correspondence address: AIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku, Tokyo 162-8655, Japan.
Tel: 81-3-3202-7181; Fax: 81-3-3208-4244; E-mail: kwatanab@acc.ncgm.go.jp

Abstract
Prolonged fever is a common symptom of COVID-19 infection. However, other febrile diseases continue during the pandemic. Herein, we report a COVID-19-infected patient with prolonged fever despite the lack of oxygen requirement, who was finally diagnosed with tuberculous lymphadenitis and HIV-1 infection. All symptoms improved rapidly after the initiation of antituberculosis medications. Tuberculosis is an important differential diagnosis for patients with prolonged fever during the COVID-19 pandemic. It is possible that COVID-19 infection could serve to unmask latent infections via a cytokine storm.

INTRODUCTION
Fever is one of the typical early clinical symptoms of COVID-19 [1]. In most cases, patients spontaneously recover without specific treatment for COVID-19. However, some patients develop acute respiratory failure with prolonged fever requiring 2–3 weeks’ recovery with anti-viral and anti-inflammatory treatments. Herein, we report a patient with COVID-19 who had prolonged fever despite the lack of oxygen demand, who was finally diagnosed with tuberculous lymphadenitis and HIV-1 infection.

Case report
A 33-year-old woman who visited a local public health care center because of a high fever was diagnosed with COVID-19 infection with polymerase chain reaction (PCR) using a nasopharyngeal swab (12 days before admission) (Fig. 1). She had no symptoms other than a fever of 39°C at diagnosis. However, her fever persisted for > 10 days. Therefore, she was admitted to our hospital on Day 0. She had immigrated from Nepal 1 year before the present illness. The patient lived with her husband and did not have a regular job. She denied close contact with anyone who had COVID-19 and tuberculosis; however, she sometimes serves customers at her husband’s restaurant. Her temperature, blood pressure, heart rate and peripheral oxygen saturation were 37.6°C, 104/75 mmHg, 107 bpm and 99% on room air, respectively. Physical examination revealed no abnormal findings, including lung sounds. Complete blood counts and biochemical testing showed no abnormalities, without mild anemia of 10.3 g/dL, C-reactive protein of 3.33 mg/dL, lactate dehydrogenase of 275 IU/L and D-dimer level of 6.1 μg/ml, respectively (Table 1).

Nasopharyngeal PCR for SARS-CoV-2 was positive on admission. Although chest X-ray revealed no abnormal findings (Fig. 2A), a computed tomography scan unexpectedly showed multiple enlarged mediastinal lymph nodes (Fig. 2B and C). As deep venous thrombosis was coincidentally identified in her left femoral vein, anticoagulant treatment (rivaroxaban) was started. Her high fever continued; therefore, we suspected other chronic infections and additionally performed an HIV test and the QuantiFERON-TB Gold test (interferon gamma release assay), which were both positive (Table 2). Her CD4+ T-cell counts and HIV-1 RNA were 63 cells/μL and 1.04 × 106 copies/ml, respectively. Although acid-fast bacillus testing and PCR for Mycobacterium tuberculosis in sputum were negative, M. tuberculosis was isolated from aspirated samples of mediastinal lymph node via bronchoscopy. With a diagnosis of tuberculous lymphadenitis, a four-drug antituberculosis regimen (isoniazid, rifabutin, pyrazinamide and ethambutol) was initiated on Day 13. We chose rifabutin instead of...
rifampicin, considering the interaction between rivaroxaban and rifampicin. The patient’s fever subsided on Day 17, and she was discharged from our hospital on Day 25. She continued therapy for 9 months. Considering the interaction with rivaroxaban, which was used for deep venous thrombosis prophylaxis, antiretroviral therapy (ART) with dolutegravir plus emtricitabine/tenofovir alafenamide were initiated on Day 35. Her CD4+ counts and HIV-RNA were 340 cells/μL and 66 copies/ml on the last follow-up date (Day 293), respectively. No immune reconstitution inflammatory syndrome (IRIS) was documented with ART.

**DISCUSSION**

We encountered a patient with prolonged fever who was diagnosed with mild COVID-19 infection. The patient was finally diagnosed as co-infected with HIV infection and extrapulmonary tuberculosis. Tuberculosis is a common cause of fever of unknown origin (FUO) [2]. It is reported that among all causes of FUO, 48.7% are owing to infectious diseases, among which tuberculosis is the most common, accounting for 19.5%. Differential diagnosis must always be considered in a patient with prolonged fever, even under conditions of the COVID-19 pandemic [3]. However, it is challenging for clinicians to determine when to consider the coexistence of other febrile diseases in COVID-19-positive cases. In the present case, we suspected the existence of the other diseases because the patient’s high fever had continued for > 10 days without oxygen desaturation. It is reported that the average duration of fever is 10 days in mild to moderate cases of COVID-19 infection and the duration of other symptoms is 11 days [4]. In the present case, deep venous thrombosis was identified as a complication of COVID-19 infection, which possibly contributed to the prolonged fever. However, high fever continued even after the initiation of anticoagulant treatment. Moreover, the patient’s fever rapidly subsides after the introduction of antituberculous regimen. Taken together, prolonged fever was caused by the tuberculous lymphadenitis in this case. It is reasonable that another etiology of fever should be considered with prolonged symptoms of 11 days or longer in patients with COVID-19 who do not have pneumonia.

Interestingly, in the present case, latent extrapulmonary tuberculosis might have been reactivated owing to COVID-19 infection. A similar case has been previously reported [5]. In that case, it could be hypothesized that latent tuberculosis infection was reactivated owing to a transient CD4+ reduction with COVID-19 infection [6]. Another possibility might be that a cytokine storm with COVID-19 infection triggered the inflammatory response to latent tuberculosis infection, which is similar to unmasking IRIS after the initiation of ART in severely immunosuppressed patients with HIV.
is well known that inflammatory cytokines, such as interleukin (IL)-1, IL-6, IL-12 and tumor necrosis factor (TNF), are heavily involved during IRIS [7]. Similarly, cytokine storms caused by COVID-19 are characterized by elevation of IL-1, IL-6, IL-12 and TNF [8–10]. The QuantiFERON-TB Gold test, which frequently yields false-negative results among immunosuppressed HIV-positive individuals [11], was positive in this case and the patient’s CD4+ count was only 63 cells/μL at diagnosis. One meta-analysis showed that co-infection of tuberculosis is a significant poor prognostic factor among COVID-19-infected patients [12]. Also, it was reported that a fatal case of rapidly progressed extrapulmonary tuberculosis was triggered by COVID-19 infection in poor-adherence HIV-1-infected patient (CD4# 105/μL at COVID-19 diagnosis) [13]. Immuno-modulating effects of COVID-19 on pre-existing infectious diseases, such as tuberculosis, have been analyzed by biological models like 3D organoids [14]. Taken together, it is possible that unmasking of latent tuberculosis infection occurred owing to a cytokine storm with COVID-19 infection, although multiple replicates should be considered to conclude it.

In conclusion, clinicians should be aware that (i) other coexisting febrile diseases are considered in mild cases of COVID-19 with prolonged fever, especially >10 days and (ii) COVID-19 infection may unmask latent opportunistic infections, such as tuberculosis, among severely immunosuppressed HIV-infected individuals.

Table 2. Laboratory data for microbiology

| Test                                    | Result                |
|-----------------------------------------|-----------------------|
| AFB blood culture (Day 2)*              | No growth             |
| AFB smear of sputum (Day 6*)            | Negative              |
| AFB culture of sputum (Day 6*)          | Negative              |
| PCR for M. tb of sputum (Day 21*)       | Negative              |
| AFB culture of aspiration from mediastinal lymph node (Day 9*) | Mycobacterium tuberculosis |
| QFT/IGRA                                | Positiveb             |
| HIV-screening (4th)                     | Positive              |
| CD4+ T-cell counts                      | 63/μL                 |
| HIV-RNA                                 | 1.04 × 10E6 copies/ml |

*Date of sample collection bNegative control (Nil) 0.68 IU/ml, Positive control (phytohemagglutinin) 1.29 IU/ml, TB1 1.38 IU/ml, TB2 1.99 IU/ml AFB, acid-fast bacilli; PCR, polymerase chain reaction; QFT/IGRA, QuantiFERON-TB Gold test/interferon-gamma release assay; HIV-screening (4th), 4th generation HIV screening assay.

ACKNOWLEDGMENTS

We thank all the staff of the National Center for Global Health and Medicine who were involved in this case. We thank Analisa Avila, MPH, ELS, of Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

CONFLICT OF INTEREST STATEMENT

No authors have any conflicts of interest related to this case report.

FUNDING

This work was supported by the Japan Agency for Medical Research and Development (AMED) [grant number 21f0410038h0001] and Grant-in Aid for AIDS research from the Japanese Ministry of Health, Labour, and Welfare (grant number: 21HB1001).

AUTHORSHIP STATEMENT

All authors meet the ICMJE authorship criteria.

ETHICAL APPROVAL

Ethical approval is not applicable in the case report.

CONSENT

Written informed consent for publication was obtained from the patient.

REFERENCES

1. Wang D, Hu B, Hu C, Zhu E, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;69:140–6.
2. Zhou G, Zhou Y, Zhong YH, Liu Z, Liu Y et al. Retrospective analysis of 1,641 cases of classic fever of unknown origin. Ann Transl Med 2020;8:690.
3. Livieri F, Ghidoni G, Piro R, Menzella F, Cavazzza A, Lazzaretti C et al. May 2020: is it always COVID-19 no matter what? Int Med Case Rep J 2020;13:563–7.
4. Lechien JR, Chiesa-Estomba CM, Place S, Laethem YV, Cabaraux P, Mat Q et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med Sep 2020,288:335–44.
5. Khayat M, Fan H, Vali Y. COVID-19 promoting the development of active tuberculosis in a patient with latent tuberculosis infection: a case report. *Respir Med Case Rep* 2021;32:101344.

6. Ho HE, Peluso MJ, Margus JP, Lopes JFM, He C, Gaisa MM et al. Clinical outcomes and immunologic characteristics of coronavirus disease 2019 in people with human immunodeficiency virus. *J Infect Dis* 2021;223:403–8.

7. Quinn CM, Poplin V, Kasibante J, Yuquimpo K, Gakuru J, Cresswell FV et al. Tuberculosis IRIS: pathogenesis, presentation, and management across the spectrum of disease. *Life (Basel)* 2020;10.262.

8. DHL N, Choy CY, Chan YH, Young B, Fong SW, LFP N et al. Fever patterns, cytokine profiles, and outcomes in COVID-19. *Open Forum Infect Dis* 2020;7 ofaa375.

9. Anka AU, Tahir MI, Abubakar SD, Alsabbagh M, Zian Z, Hamedifar H et al. Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management. *Scand J Immunol* 2021;93:e12998.

10. Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. *Theranostics* 2021;11:316–29.

11. Kwon YS, Kim YH, Jeon K, Jeong BH, Ryu YJ, Choi JC et al. Factors that predict negative results of QuantiFERON-TB gold in-tube test in patients with culture-confirmed tuberculosis: a multicenter retrospective cohort study. *PLoS One* 2015;10.e0129792.

12. Sakar S, Khanna P, Singh AK. Impact of COVID-19 in patients with concurrent co-infections: a systematic review and meta-analyses. *J Med Virol* 2021;93:2385–95.

13. Ortiz-Martínez Y, Mogollón-Vargas JM, López-Rodríguez M, Rodríguez-Morales A. A fatal case of triple coinfection: COVID-19, HIV and tuberculosis. *Travel Med Infect Dis* 2021;43:102129.

14. Devi P, Khan A, Chattopahyay P, Mehta P, Sahni S, Sharma S et al. Co-infections as modulators of disease outcome: minor players or major players? *Front Microbiol* 2021;12:664386.